Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C8H15N2O5P |
Molecular Weight | 250.1889 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1
InChI
InChIKey=VZXMZMJSGLFKQI-ABVWVHJUSA-N
InChI=1S/C8H15N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h1,5,7,9H,2-4,6H2,(H,11,12)(H2,13,14,15)/b5-1+/t7-/m1/s1
Molecular Formula | C8H15N2O5P |
Molecular Weight | 250.1889 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Midafotel (CPPene; SDZ EAA 494) is a selective competitive antagonist at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. It was originally designed as a potential therapy for excitotoxicity, epilepsy or neuropathic pain. Midafotel had been in phase III clinical trials by Novartis for the treatment of brain injury. However, this research has been discontinued.
Originator
Sources: http://adisinsight.springer.com/drugs/800002722
Curator's Comment: # Novartis
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
199 ng/mL |
1000 mg 2 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MIDAFOTEL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20 h |
1000 mg 2 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MIDAFOTEL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg single, intravenous (unknown) Highest studied dose Dose: 50 mg Route: intravenous Route: single Dose: 50 mg Sources: |
healthy n = 9 Health Status: healthy Sex: M Food Status: UNKNOWN Population Size: 9 Sources: |
|
25 mg 2 times / day multiple, intravenous (unknown) Overdose Dose: 25 mg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg, 2 times / day Sources: |
healthy n = 9 Health Status: healthy Sex: M Food Status: UNKNOWN Population Size: 9 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Blockade of hindbrain NMDA receptors containing NR2 subunits increases sucrose intake. | 2009 Apr |
|
NMDA NR2 receptors participate in CCK-induced reduction of food intake and hindbrain neuronal activation. | 2009 Apr 17 |
|
Pharmacological characterization of harmaline-induced tremor activity in mice. | 2009 Aug 15 |
|
Reduction of food intake by cholecystokinin requires activation of hindbrain NMDA-type glutamate receptors. | 2011 Aug |
|
An examination of NMDA receptor contribution to conditioned responding evoked by the conditional stimulus effects of nicotine. | 2011 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8740048
Midafotel was administered either as single doses at a dose range of 1-50 mg, or as multiple doses over the course of 1 week at doses of 25 mg once or twice daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12787951
Midafotel (d-CPPene) strongly inhibited the frequency of spontaneous
epileptiform discharges. This effect was concentration-dependent.
Epileptiform discharges were reduced up to 70% at a concentration of 0.1 uM and were completely blocked at a concentration of 0.3 uM in the rat cortical wedge preparation. d-CPPene inhibited in concentration-dependent manner
NMDA-induced depolarisations. A concentration of 0.1 uM
that blocked 70% of spontaneous discharges inhibited 60%
of depolarisations induced by NMDA. A concentration of
1 uM completely blocked NMDA-induced depolarisations.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:57:15 GMT 2023
by
admin
on
Fri Dec 15 15:57:15 GMT 2023
|
Record UNII |
7LYU6ZF84G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WIKIPEDIA |
NMDA receptor antagonist
Created by
admin on Fri Dec 15 15:57:16 GMT 2023 , Edited by admin on Fri Dec 15 15:57:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7736
Created by
admin on Fri Dec 15 15:57:15 GMT 2023 , Edited by admin on Fri Dec 15 15:57:15 GMT 2023
|
PRIMARY | |||
|
C167034
Created by
admin on Fri Dec 15 15:57:15 GMT 2023 , Edited by admin on Fri Dec 15 15:57:15 GMT 2023
|
PRIMARY | |||
|
117414-74-1
Created by
admin on Fri Dec 15 15:57:15 GMT 2023 , Edited by admin on Fri Dec 15 15:57:15 GMT 2023
|
PRIMARY | |||
|
6435801
Created by
admin on Fri Dec 15 15:57:15 GMT 2023 , Edited by admin on Fri Dec 15 15:57:15 GMT 2023
|
PRIMARY | |||
|
SUB03287MIG
Created by
admin on Fri Dec 15 15:57:15 GMT 2023 , Edited by admin on Fri Dec 15 15:57:15 GMT 2023
|
PRIMARY | |||
|
MIDAFOTEL
Created by
admin on Fri Dec 15 15:57:15 GMT 2023 , Edited by admin on Fri Dec 15 15:57:15 GMT 2023
|
PRIMARY | |||
|
100000085981
Created by
admin on Fri Dec 15 15:57:15 GMT 2023 , Edited by admin on Fri Dec 15 15:57:15 GMT 2023
|
PRIMARY | |||
|
7LYU6ZF84G
Created by
admin on Fri Dec 15 15:57:15 GMT 2023 , Edited by admin on Fri Dec 15 15:57:15 GMT 2023
|
PRIMARY | |||
|
CHEMBL90564
Created by
admin on Fri Dec 15 15:57:15 GMT 2023 , Edited by admin on Fri Dec 15 15:57:15 GMT 2023
|
PRIMARY | |||
|
DTXSID1045740
Created by
admin on Fri Dec 15 15:57:15 GMT 2023 , Edited by admin on Fri Dec 15 15:57:15 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
COMPETITIVE INHIBITOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|